Neogen Corporation - Common Stock (NEOG)
Healthcare › In Vitro & In Vivo Diagnostic Substances
Investment Snapshot
- P/B of 1.10 — trading near book value
- Low leverage — D/E ratio of 0.42
- Loss-making — negative ROE of -21.2%
Neogen Corporation - Common Stock (NEOG) is a Healthcare company operating in In Vitro & In Vivo Diagnostic Substances, listed on the NASDAQ , with a market capitalisation of $2.3 billion . Key value metrics: P/B ratio 1.10.
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Neogen Corporation - Common Stock — Fundamental Analysis Summary
On financial health, NEOG shows negative return on equity of -21.2% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.42.
StockPik's composite Value Score for NEOG is 67/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
NEOG reports a solid gross margin of 48.0% (sector average: 33.5%) and a negative operating margin of -53.4%.